Ciphergen, OSU Research Foundation Collaborate on Dx Test for TTP
Ciphergen and the Ohio State University Research Foundation announced this week a collaboration to develop a diagnostic test for thrombotic thrombocytopenic purpura using the SELDI platform.
Under terms of the agreement, the two parties will “optimize” a SELDI-based test to measure enzyme and antibody inhibition activity and jointly conduct multi-center studies to validate the test. Financial terms of the deal were not disclosed.
In a statement, Haifeng Wu, an assistant professor of pathology and medicine and director of the clinical coagulation laboratory at OSU Medical Center, said a potential test will help physicians determine “when to initiate plasma exchange and monitor responses to this therapy.”
Revenues for Bruker Daltonics Slightly Down in Q3
In a filing with the US Securities and Exchange Commission, Bruker said revenues for its Daltonics division slid 1.8 percent to $36.3 million for its third quarter from $36.9 million during the year-ago period.
The Daltonics division houses Bruker’s instruments with proteomics applications. The $36.3 million comprised 34.6 percent of Bruker’s $104.9 million in total revenues for the three months ended Sept. 30 [See PM 11/02/06]. Within the division, life science systems accounted for $26.4 million in revenues, compared to $26.6 million a year ago.
Bruker said revenues for its AXS division were $47 million while its Optics division recorded $24.5 million in revenues.
During the first nine months of 2006, the Daltonics division had $113.7 million in revenues, compared to $117 million a year ago.
Alfa Wassermann, Pressure BioSciences Reach Deal on Sample Prep Methods
Alfa Wassermann Proteomic Technologies and Pressure BioSciences said this week they will collaborate on developing sample preparation methods to enrich for low-abundance proteins and sub-cellular complexes from cells and tissues.
AWPT’s AW Promatix 1000 and PBI’s Pressure Cycling Technology will be used to develop the methods.
The agreement is for three months and can be extended by mutual agreement. Any IP developed as a result of the deal will be co-owned. The agreement also calls for the cross-licensing of new IP to allow each company to have global, exclusive, royalty-free licenses in their area of focus, the companies said in a statement. Each company will pay the majority of costs incurred by its internal research efforts.
Dyax and Aussie Agency Partner on Antibody Discovery and Development
Dyax has entered into a collaboration with Australia’s Division of Molecular and Health Technologies of the Commonwealth Scientific and Industrial Research Organization for the discovery and development of antibodies for the treatment of cancer.
The CSIRO is Australia’s national scientific research agency. Financial terms of the agreement were not disclosed.
Under the agreement, Dyax will use its proprietary antibody libraries to screen for clinical candidates. CSIRO will provide the reagents and in vitro assays and certain in vivo and preclinical development work.
If antibodies are found, both CSIRO and Dyax have the option of advancing the antibodies to clinical development under a global co-development and commercialization agreement.
Dyax, based in Cambridge, Mass., is focused on developing novel biotherapeutics, especially for oncology and inflammatory indications. Its lead product is DX-88, a recombinant small protein currently in clinical trials for the treatment of hereditary angioedema and the prevention of blood loss during on-pump coronary artery bypass graft procedures.
NIH Requiring R01 Grant Applications Online
Starting Feb. 5, all National Institutes of Health research project grant R01 applications will have to be filed electronically, the NIH said this week.
The NIH recommends all principal investigators to contact their central grants offices to learn how their institutions are handling the application form and process changes. On Dec. 5, NIH is hosting a training session to help applicants through the transition. The training is available via Webcast here. The session will be archived.
Information on the submission process and additional training is available on the NIH Electronic Submission of Grant Application Web site here.